Influence of a fatty beverage (Milk) on the absorption of erlotinib: a randomized, cross-over pharmacokinetic study (MERLOT-study)

Influence of a fatty beverage (Milk) on the absorption of erlotinib: a randomized, cross-over pharmacokinetic study (MERLOT-study) - Influence of milk on erlotinib

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43280

Enrollment

Registered

2016-12-19

Start date

2017-02-22

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Erlotinib

Milk

Non-Small Cell Lung Cancer

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age * 18 2. Use of erlotinib monotherapy for at least 14 days (to guarantee steady-state) and willing to continue the treatment until the end of the study 3. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations

Exclusion criteria

Exclusion criteria: 1. Age

Design outcomes

Primary

Measure	Time frame
The difference in the bioavailabiliteit of erlotinib in patients taking a PPI or not , with or without milk.	—

Secondary

Measure	Time frame
Comparison of toxicity and side effects of erlotinib taken with water or milk .	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)